LifeMD (LFMD) Stock Forecast & Price Target

LifeMD is viewed positively because its direct-to-patient model is gaining scale through high-value partnerships, especially the exclusive AT&T collaboration that could funnel more than 100 million eligible customers to its platform without additional acquisition cost and may begin contributing meaningfully to topline revenue in 4Q26. The company also has improving retention and lifetime value dynamics, as about 95% of new weight management patients start on branded GLP-1 therapies and multi-month package adoption rose from roughly 25% year to date before the pricing change to about 85% afterward, while weight management subscribers reached approximately 108,000 and active subscribers grew 20% YoY to about 356,000. Even after a 2Q26 revenue miss to $47.3M and FY2026 guidance cut to $205.5M-$212.5M, management sees a path to positive adjusted EBITDA in 2H26, supported by women’s health acceleration, XYOSTED, expanded insurance coverage, and a broader telehealth platform.

LifeMD is viewed negatively because its valuation already depends on aggressive revenue assumptions, yet it still trades at only 0.8x 2027E revenue and 2.0x projected EV/Revenue, suggesting the market is skeptical about execution. Its downside risks are substantial: slower telehealth revenue growth, weak patient acquisition and retention, inability to reach sustained profitability, intense competition, dilution, cybersecurity threats, and regulatory/compliance pressures in a highly regulated healthcare market. Although it recently turned EBITDA-positive, the long period of prior losses and reliance on growth strategies that may not work make the business profile fragile and the shares vulnerable to disappointment.